Uterine Leiomyosarcoma in a Patient with Classic Presentation Of
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Uterine Sarcomas: a Review
ARTICLE IN PRESS YGYNO-973334; No. of pages: 9; 4C: 3, 6 Gynecologic Oncology xxx (2009) xxx–xxx Contents lists available at ScienceDirect Gynecologic Oncology journal homepage: www.elsevier.com/locate/ygyno Review Uterine sarcomas: A review Emanuela D'Angelo, Jaime Prat ⁎ Department of Pathology, Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona, Sant Antoni M. Claret, 167, 08025 Barcelona, Spain article info abstract Article history: Objective. Uterine sarcomas are rare tumors that account for 3% of uterine cancers. Their histopathologic Received 29 June 2009 classification was revised by the World Health Organization (WHO) in 2003. A new staging system has been Available online xxxx recently designed by the International Federation of Gynecology and Obstetrics (FIGO). Currently, there is no consensus on risk factors for adverse outcome. This review summarizes the available clinicopathological data Keywords: on uterine sarcomas classified by the WHO diagnostic criteria. Uterine sarcomas Methods. Medline was searched between 1976 and 2009 for all publications in English where the studied Leiomyosarcoma population included women diagnosed of uterine sarcomas. Endometrial stromal sarcoma fi Undifferentiated endometrial sarcoma Results. Since carcinosarcomas (malignant mixed mesodermal tumors or MMMT) are currently classi ed Adenosarcoma as metaplastic carcinomas, leiomyosarcomas remain the most common uterine sarcomas. Exclusion of Carcinosarcoma several histologic variants of leiomyoma, as well as “smooth muscle tumors of uncertain malignant potential,” frequently misdiagnosed as sarcomas, has made apparent that leiomyosarcomas are associated with poor prognosis even when seemingly confined to the uterus. Endometrial stromal sarcomas are indolent tumors associated with long-term survival. Undifferentiated endometrial sarcomas exhibiting nuclear pleomorphism behave more aggressively than tumors showing nuclear uniformity. -
Ovarian Cancer and Cervical Cancer
What Every Woman Should Know About Gynecologic Cancer R. Kevin Reynolds, MD The George W. Morley Professor & Chief, Division of Gyn Oncology University of Michigan Ann Arbor, MI What is gynecologic cancer? Cancer is a disease where cells grow and spread without control. Gynecologic cancers begin in the female reproductive organs. The most common gynecologic cancers are endometrial cancer, ovarian cancer and cervical cancer. Less common gynecologic cancers involve vulva, Fallopian tube, uterine wall (sarcoma), vagina, and placenta (pregnancy tissue: molar pregnancy). Ovary Uterus Endometrium Cervix Vagina Vulva What causes endometrial cancer? Endometrial cancer is the most common gynecologic cancer: one out of every 40 women will develop endometrial cancer. It is caused by too much estrogen, a hormone normally present in women. The most common cause of the excess estrogen is being overweight: fat cells actually produce estrogen. Another cause of excess estrogen is medication such as tamoxifen (often prescribed for breast cancer treatment) or some forms of prescribed estrogen hormone therapy (unopposed estrogen). How is endometrial cancer detected? Almost all endometrial cancer is detected when a woman notices vaginal bleeding after her menopause or irregular bleeding before her menopause. If bleeding occurs, a woman should contact her doctor so that appropriate testing can be performed. This usually includes an endometrial biopsy, a brief, slightly crampy test, performed in the office. Fortunately, most endometrial cancers are detected before spread to other parts of the body occurs Is endometrial cancer treatable? Yes! Most women with endometrial cancer will undergo surgery including hysterectomy (removal of the uterus) in addition to removal of ovaries and lymph nodes. -
About Ovarian Cancer Overview and Types
cancer.org | 1.800.227.2345 About Ovarian Cancer Overview and Types If you have been diagnosed with ovarian cancer or are worried about it, you likely have a lot of questions. Learning some basics is a good place to start. ● What Is Ovarian Cancer? Research and Statistics See the latest estimates for new cases of ovarian cancer and deaths in the US and what research is currently being done. ● Key Statistics for Ovarian Cancer ● What's New in Ovarian Cancer Research? What Is Ovarian Cancer? Cancer starts when cells in the body begin to grow out of control. Cells in nearly any part of the body can become cancer and can spread. To learn more about how cancers start and spread, see What Is Cancer?1 Ovarian cancers were previously believed to begin only in the ovaries, but recent evidence suggests that many ovarian cancers may actually start in the cells in the far (distal) end of the fallopian tubes. 1 ____________________________________________________________________________________American Cancer Society cancer.org | 1.800.227.2345 What are the ovaries? Ovaries are reproductive glands found only in females (women). The ovaries produce eggs (ova) for reproduction. The eggs travel from the ovaries through the fallopian tubes into the uterus where the fertilized egg settles in and develops into a fetus. The ovaries are also the main source of the female hormones estrogen and progesterone. One ovary is on each side of the uterus. The ovaries are mainly made up of 3 kinds of cells. Each type of cell can develop into a different type of tumor: ● Epithelial tumors start from the cells that cover the outer surface of the ovary. -
Photodynamic Therapy for Gynecological Diseases and Breast Cancer
CancCancerer Biol Med 2012;2012 /9: Vol. 9-17 9 /doi: No. 10.3969/j.issn.2095-3941.2012.1 01.002 9 Review Photodynamic Therapy for Gynecological Diseases and Breast Cancer Natashis Shishkova, Olga Kuznetsova, Temirbolat Berezov Department of Biochemistry, School of Medicine, People’s Friendship University of Russia, Moscow 117198, Russia ABSTRACT Photodynamic therapy (PDT) is a minimally invasive and promising new method in cancer treatment. Cytotoxic reactive oxygen species (ROS) are generated by the tissue-localized non-toxic sensitizer upon illumination and in the presence of oxygen. Thus, selective destruction of a targeted tumor may be achieved. Compared with traditional cancer treatment, PDI has advantages including higher selectivity and lower rate of toxicity. The high degree of selectivity of the proposed method was applied to cancer diagnosis using fluorescence. This article reviews previous studies done on PDT treatment and photodetection of cervical intraepithelial neoplasia, vulvar intraepithelial neoplasia, ovarian and breast cancer, and PDT application in treating non-cancer lesions. The article also highlights the clinical responses to PDT, and discusses the possibility of enhancing treatment efficacy by combination with immunotherapy and targeted therapy. KEY WORDS: photodynamic therapy, photosensitizers, cervical/vulvar intraepithelial neoplasia, ovarian neoplasms, breast neoplasms Introduction frequently used drug in PDT is 5-aminolaevulinic acid (ALA). However, 5-ALA is not a photosensitizer, but a precursor of Photodynamic therapy (PDT) is a mode of therapy used in the endogenous photosensitizer protoporphyrin IX, which is cancer treatment where drug activity is locally controlled by a member of the heme synthesis pathway that occurs in the light (Figure 1). -
What Is New on Ovarian Carcinoma
diagnostics Review What Is New on Ovarian Carcinoma: Integrated Morphologic and Molecular Analysis Following the New 2020 World Health Organization Classification of Female Genital Tumors Antonio De Leo 1,2,3,*,† , Donatella Santini 3,4,† , Claudio Ceccarelli 1,3, Giacomo Santandrea 5 , Andrea Palicelli 5 , Giorgia Acquaviva 1,2, Federico Chiarucci 1,2 , Francesca Rosini 4, Gloria Ravegnini 3,6 , Annalisa Pession 2,6, Daniela Turchetti 3,7, Claudio Zamagni 8, Anna Myriam Perrone 3,9 , Pierandrea De Iaco 3,9, Giovanni Tallini 1,2,3,‡ and Dario de Biase 2,3,6,‡ 1 Department of Experimental, Diagnostic and Specialty Medicine, Alma Mater Studiorum—University of Bologna, Via Massarenti 9, 40138 Bologna, Italy; [email protected] (C.C.); [email protected] (G.A.); [email protected] (F.C.); [email protected] (G.T.) 2 Molecular Pathology Laboratory, IRCCS Azienda Ospedaliero—Universitaria di Bologna/Azienda USL di Bologna, 40138 Bologna, Italy; [email protected] (A.P.); [email protected] (D.d.B.) 3 Centro di Studio e Ricerca delle Neoplasie Ginecologiche, Alma Mater Studiorum—University of Bologna, 40138 Bologna, Italy; [email protected] (D.S.); [email protected] (G.R.); [email protected] (D.T.); [email protected] (A.M.P.); [email protected] (P.D.I.) 4 Pathology Unit, IRCCS Azienda Ospedaliero—Universitaria di Bologna, Via Massarenti 9, 40138 Bologna, Italy; [email protected] 5 Citation: De Leo, A.; Santini, D.; Pathology Unit, AUSL-IRCCS di Reggio Emilia, 42122 Reggio Emilia, Italy; Ceccarelli, C.; Santandrea, G.; [email protected] (G.S.); [email protected] (A.P.) 6 Palicelli, A.; Acquaviva, G.; Chiarucci, Department of Pharmacy and Biotechnology, University of Bologna, 40126 Bologna, Italy 7 Unit of Medical Genetics, IRCCS Azienda Ospedaliero—Universitaria di Bologna, Via Massarenti 9, F.; Rosini, F.; Ravegnini, G.; Pession, 40138 Bologna, Italy A.; et al. -
ASCO Answers: Ovarian, Fallopian Tube, and Peritoneal Cancer
Ovarian, Fallopian Tube & Peritoneal Cancer What are ovarian, fallopian tube, and peritoneal cancers? The term “ovarian cancer” is often used to describe cancers that begin in the cells in the ovary, fallopian tube, and peritoneum. These types of cancer begin when healthy cells in these areas change and grow out of control, forming a mass called a tumor. Research suggests that high-grade serous cancer, which includes most ovarian cancer, usually starts in the fallopian tubes. Some peritoneal cancers also may begin in the fallopian tube. What are the functions of the ovaries, fallopian tubes, and peritoneum? The ovaries and fallopian tubes are part of a woman’s reproductive system. Typically, every woman has 2 ovaries, which contain eggs and are the primary source of estrogen and progesterone. These hormones play a role in breast growth, body shape, body hair, the menstrual cycle, and pregnancy. ONCOLOGY. CLINICAL AMERICAN SOCIETY OF 2004 © LLC. EXPLANATIONS, MORREALE/VISUAL ROBERT BY ILLUSTRATION There are 2 fallopian tubes, which are small ducts that link the ovaries to the uterus. During a woman’s monthly ovulation, an egg is usually released from 1 ovary and travels through the fallopian tube to the uterus. The peritoneum is a tissue that lines the abdomen and most of the organs in the abdomen. What do stage and grade mean? Staging is a way of describing a cancer’s location, if or where it has spread, and whether it is affecting other parts of the body. There are 4 stages for ovarian, fallopian tube, and peritoneal cancer: stages I through IV (1 through 4). -
Role of Surgery in Gynaecological Sarcomas
www.oncotarget.com Oncotarget, 2019, Vol. 10, (No. 26), pp: 2561-2575 Review Role of surgery in gynaecological sarcomas Valentina Ghirardi1,2, Nicolò Bizzarri1,2, Francesco Guida1,2, Carmine Vascone1,2, Barbara Costantini1,2, Giovanni Scambia1,2 and Anna Fagotti1,2 1Division of Gynecologic Oncology, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome 00168, Italy 2Catholic University of Sacred Heart, Rome 00168, Italy Correspondence to: Anna Fagotti, email: [email protected] Keywords: sarcoma; uterine; cervical; ovarian; vulval Received: November 01, 2018 Accepted: January 19, 2019 Published: April 02, 2019 Copyright: Ghirardi et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. ABSTRACT Gynaecological sarcomas account for 3-4% of all gynaecological malignancies and have a poorer prognosis compared to gynaecological carcinomas. Pivotal treatment for early-stage uterine sarcoma is represented by total hysterectomy. Whereas oophorectomy provides survival advantage in endometrial stromal sarcoma is still controversial. When the disease is confined to the uterus, systematic pelvic and para- aortic lymphadenectomy is not recommended. Removal of enlarged lymph-nodes is indicated in case of disseminated or recurrent disease, where debulking surgery is considered the standard of care. Fertility sparing surgery for uterine leiomyosarcoma is not supported by strong evidence, whilst available data on fertility sparing treatment for endometrial stromal sarcoma are more promising. For ovarian sarcomas, in the absence of specific data, it is reasonable to adapt recommendations existing for uterine sarcomas, also regarding the role of lymphadenectomy in both early and advanced stage disease. -
A Case Report
International Journal of Reproduction, Contraception, Obstetrics and Gynecology Kurude VN et al. Int J Reprod Contracept Obstet Gynecol. 2017 Mar;6(3):1149-1150 www.ijrcog.org pISSN 2320-1770 | eISSN 2320-1789 DOI: http://dx.doi.org/10.18203/2320-1770.ijrcog20170605 Case Report Dysgermgerminoma in a 14 year old girl: a case report V. N. Kurude*, Sukanya Thorat Department of Obstetrics and Gynecology, Grant Medical College and Sir Jamshedjee Jeejeebhoy Group of Hospitals, Mumbai, Maharashtra, India Received: 27 December 2016 Revised: 07 January 2017 Accepted: 31 January 2017 *Correspondence: Dr. V. N. Kurude, E-mail: [email protected] Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. ABSTRACT An accurate diagnosis of ovarian dysgerminoma is crucial as, as its management differs from other ovarian tumours. We report a case of ovarian dyegerminoma in a 14 year old girl who presented with abdominal distention. Examination revealed a huge intra-abdominal mass causing displacement of bowel loops laterally. On ultrasound, a solid heterogeneously hyperechoic lesion of size 18 x 9.4 cm with few cystic and necrotic areas within most likely, left adnexa reaching upto the umbilicus and shows vascularity within both ovaries not seen separately from the lesion. On CT (A+P), a heterogenous hypodense polycystic mass of size 8.5x1.4x16.7 with multiple irregular hypodensities seen in the lower abdomen and pelvis. -
Phytochemicals in Gynecological Cancer Prevention
International Journal of Molecular Sciences Review Phytochemicals in Gynecological Cancer Prevention Marta Wo´zniak 1, Rafał Krajewski 2, Sebastian Makuch 1 and Siddarth Agrawal 1,2,3,* 1 Department of Pathology, Wroclaw Medical University, 50-368 Wroclaw, Poland; [email protected] (M.W.); [email protected] (S.M.) 2 Department and Clinic of Internal Medicine, Occupational Diseases, Hypertension and Clinical Oncology, Wroclaw Medical University, 50-556 Wroclaw, Poland; [email protected] 3 Department of Cancer Prevention and Therapy, Wroclaw Medical University, 50-556 Wroclaw, Poland * Correspondence: [email protected] Abstract: Gynecological cancer confers an enormous burden among women worldwide. Accu- mulating evidence points to the role of phytochemicals in preventing cervical, endometrial, and ovarian cancer. Experimental studies emphasize the chemopreventive and therapeutic potential of plant-derived substances by inhibiting the early stages of carcinogenesis or improving the efficacy of traditional chemotherapeutic agents. Moreover, a number of epidemiological studies have investi- gated associations between a plant-based diet and cancer risk. This literature review summarizes the current knowledge on the phytochemicals with proven antitumor activity, emphasizing their effectiveness and mechanism of action in gynecological cancer. Keywords: phytochemicals; gynecological cancers; anticancer 1. Introduction Citation: Wo´zniak,M.; Krajewski, Currently, there is a dynamic increase in the number of cancer cases around the world. R.; Makuch, S.; Agrawal, S. A total of 18.1 million new cases were reported in 2018, of which nearly 10 million were Phytochemicals in Gynecological fatal [1]. It is estimated that a prolonged human lifespan and limited access to highly Cancer Prevention. Int. J. Mol. -
Case Report Metastatic Uterine Leiomyosarcoma Involving Bilateral Ovarian Stroma Without Capsular Involvement Implies a Local Route of Hematogenous Dissemination
Hindawi Publishing Corporation Case Reports in Obstetrics and Gynecology Volume 2015, Article ID 950373, 5 pages http://dx.doi.org/10.1155/2015/950373 Case Report Metastatic Uterine Leiomyosarcoma Involving Bilateral Ovarian Stroma without Capsular Involvement Implies a Local Route of Hematogenous Dissemination Monica Dandapani,1 Brandon-Luke L. Seagle,1 Amer Abdullah,1 Bryce Hatfield,2 Robert Samuelson,1 and Shohreh Shahabi3 1 Department of Obstetrics, Gynecology and Reproductive Biology, Western Connecticut Health Network, 24 Hospital Avenue, Danbury, CT 06810, USA 2Department of Pathology, Western Connecticut Health Network, 24 Hospital Avenue, Danbury, CT 06810, USA 3Division of Gynecologic Oncology, Northwestern University Feinberg School of Medicine, 250 East Superior Street, Suite 03-2303, Chicago, IL 60611, USA Correspondence should be addressed to Shohreh Shahabi; [email protected] Received 2 March 2015; Accepted 9 April 2015 Academic Editor: Hao Lin Copyright © 2015 Monica Dandapani et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Uterine sarcomas spread via lymphatic and hematogenous dissemination, direct extension, or transtubal transport. Distant metastasis often involves the lungs. Ovarian metastasis is uncommon. Here we present an unusual case of a large, high-grade uLMS with metastatic disease internal to both ovaries without capsular involvement or other abdominal diseases, and discovered in a patient with distant metastases to the lungs, suggesting likely hematogenous dissemination of uLMS to the ovaries in this case. Knowledge of usual uLMS metastases may influence surgical management in select cases. -
The Landscape and Therapeutic Implications of Molecular Profiles In
Journal of Clinical Medicine Review The Landscape and Therapeutic Implications of Molecular Profiles in Epithelial Ovarian Cancer Ludivine Dion 1,2,3 , Isis Carton 1,2, Sylvie Jaillard 2,3,4, Krystel Nyangoh Timoh 1,2, Sébastien Henno 5, Hugo Sardain 1, Fabrice Foucher 1, Jean Levêque 1,2, Thibault de la Motte Rouge 6, Susie Brousse 1,2 and Vincent Lavoué 1,2,3,* 1 Service de Chirurgie gynécologique, CHU de Rennes, 35000 Rennes, France; [email protected] (L.D.); [email protected] (I.C.); [email protected] (K.N.T.); [email protected] (H.S.); [email protected] (F.F.); [email protected] (J.L.); [email protected] (S.B.) 2 Faculté de médecine, Université de Rennes 1, 35000 Rennes, France; [email protected] 3 INSERM U 1085, IRSET, Equipe 8, 35000 Rennes, France 4 Service de Cytogénétique, CHU de Rennes, 35000 Rennes, France 5 Service d’anatomo-pathologie, CHU de Rennes, 35000 Rennes, France; [email protected] 6 Service d’oncologie médicale, CRLCC Eugène Marquis, 35000 Rennes, France; [email protected] * Correspondence: [email protected] Received: 24 April 2020; Accepted: 10 July 2020; Published: 15 July 2020 Abstract: Epithelial ovarian cancer (EOC) affects 43,000 women worldwide every year and has a five-year survival rate of 30%. Mainstay treatment is extensive surgery and chemotherapy. Outcomes could be improved by molecular profiling. We conducted a review of the literature to identify relevant publications on molecular and genetic alterations in EOC. -
Gynecologic Malignancies J
Gynecologic Malignancies J. Brian Szender 31 March 2016 Outline • Female Cancer Statistics • Uterine Cancer • Adnexal Cancer • Cervical Cancer • Vulvar Cancer Uterine Cancer Endometrial Cancer Uterine Sarcoma Endometrial Cancer • Epidemiology and Risk Factors • Histology • Presentation • Diagnosis • Staging • Therapy • Early • Locally Advanced • Metastatic • Recurrent • Follow-Up • Future Therapy Epidemiology • 60,500 cases expected in 2016 • 25.3 per 100,000 women • 10,470 deaths expected in 2016 Epidemiology Increased Risk Decreased Risk • Age • Progestational Agents • Unopposed Estrogens • Oral Contraceptive Pills • Exogenous • Levonorgestrel IUS • Tamoxifen • Physical Activity • Obesity • Pregnancy • Genetic Risk • Breastfeeding • Lynch Syndrome • Cowden Syndrome Histology • Type I • Endometrioid, well differentiated • Less aggressive • Usually localized • Good Prognosis • Type II • Clear cell, papillary serous, MMMT, poorly differentiated • More aggressive • Likely to spread • Worse Prognosis Histology – Molecular Features Type I Type II • Diploid • Aneuploid • K-ras overexpression • K-ras overexpression • PTEN mutations • P53 overexpression • Microsatellite instability Clinical Presentation • Abnormal Uterine Bleeding • Postmenopausal Uterine Bleeding • Abnormal Vaginal Discharge • Endometrial cells on a pap smear • Bloating/pelvic pressure/pain (if advanced disease) Diagnosis • Ultrasound • Endometrial Biopsy • Hysteroscopy • Dilation and Curettage • Hysterectomy +/- BSO +/- Lymph node sampling Staging wikipedia Therapy – Early